Table 1.
LncRNAs | Regulation after AMI | Relation to other biomarkers | |
---|---|---|---|
Yan et al. 41 | UCA1 | Down‐regulation | Inversely related to miR‐1 level |
Zangrando et al. 42 | MIRT1/MIRT2 | Up‐regulation | Negatively correlated with infarct size; positively correlated with EF value |
Zhang et al. 43 | MHRT | Up‐regulation | Inversely related to cardiomyocyte apoptosis |
Vausort et al. 56 | ANRIL | Down‐regulation | Positively correlated to lymphocytes and monocytes; negatively related to MMP9, WBC, neutrophils, platelets |
Vausort et al. 56 | MIAT | Down‐regulation | Positively related to lymphocytes; negatively related to neutrophils, platelets |
Vausort et al. 56 | MALAT1 | Up‐regulation | Negatively related to platelets |
Vausort et al. 56 | aHIF | Up‐regulation | Positively related to WBC, neutrophils CRP, MMP9, TIMP1; negatively related to lymphocytes |
Qu et al. 80 | NONMMUT022554 | Up‐regulation | Positively correlated with fibrosis gene expression |
ANRIL, cyclin‐dependent kinase inhibitor 2B antisense RNA 1; aHIF, hypoxia‐inducible factor 1A antisense RNA 2; CRP, C‐reactive protein; EF, ejection fraction; MIRT1, MI‐associated transcript 1; MIRT2, MI‐associated transcript 2; MIAT, myocardial infarction‐associated transcript; MALAT1. metastasis‐associated lung adenocarcinoma transcript 1; MMP9, matrix metalloproteinase 9; TIMP1, tissue inhibitor of metalloproteinase 1; UCA1, urothelial carcinoma‐associated 1; WBC, white blood cell.